Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.
Conditions Studied
Interventions
- DRUG PF-07799544
- DRUG PF-07799933
Study Locations (20)
California
- The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate — Los Angeles
- Keck Hospital of USC — Los Angeles
- Los Angeles General Medical Center — Los Angeles
- USC/Norris Comprehensive Cancer Center — Los Angeles
- Keck Medical Center of USC Pasadena — Pasadena
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco
- UCSF Medical Center, Investigational Pharmacy — San Francisco
- The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only) — Santa Monica
Alabama
- The Kirklin Clinic of UAB Hospital — Birmingham
- The University of Alabama at Birmingham — Birmingham
- University of Alabama at Birmingham - Phase I Clinical Trials Unit — Birmingham
Arkansas
- Highlands Oncology Group, PA — Fayetteville
- Highlands Oncology Group, PA — Rogers
- Highlands Oncology Group, PA — Springdale
Florida
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center — Tampa
- Moffitt Cancer Center — Tampa
- Moffitt McKinley Hospital — Tampa
Massachusetts
- Brigham and Women's Hospital — Boston
- Dana Farber Cancer Institute — Boston
Louisiana
- Ochsner Clinic Foundation — New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2028-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05538130
The ClinicalTrials.gov registry entry for NCT05538130 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions — of which PF-07799544 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05538130 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Alabama, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05538130 about?
NCT05538130 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors". The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 ...
What is the current status of trial NCT05538130?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2022-11-30. Estimated completion is 2028-10-07.
What conditions does trial NCT05538130 study?
This clinical trial studies the following conditions: Melanoma, Non-Small Cell Lung Cancer, Glioma, Thyroid Cancer, Advanced or Metastatic Solid Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05538130?
The interventions under investigation include: PF-07799544 (DRUG), PF-07799933 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05538130?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05538130 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.